Efficacy and safety of travoprost/timolol vs dorzolamide/timolol in patients with open-angle glaucoma or ocular hypertension

Miguel A Teus1, Stefano Miglior2, Guna Laganovska3, Lasma Volksone4, Bozena Romanowska-Dixon5, Roman Gos6, G&aacute;bor Holl&oacute;7, for the C-05-25 Study Group81Hospital Pr&iacute;ncipe de Ast&uacute;rias, Universidad de Alcal&aacute;, Madrid, Spain; 2Clini...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Miguel A Teus, Stefano Miglior, Guna Laganovska, et al
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2009
Materias:	Ophthalmology RE1-994
Acceso en línea:	https://doaj.org/article/fe73aafe56dd429cb0d2fa9f00d86f07
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:fe73aafe56dd429cb0d2fa9f00d86f07
record_format	dspace
spelling	oai:doaj.org-article:fe73aafe56dd429cb0d2fa9f00d86f072021-12-02T08:08:06ZEfficacy and safety of travoprost/timolol vs dorzolamide/timolol in patients with open-angle glaucoma or ocular hypertension1177-54671177-5483https://doaj.org/article/fe73aafe56dd429cb0d2fa9f00d86f072009-11-01T00:00:00Zhttp://www.dovepress.com/efficacy-and-safety-of-travoprosttimolol-vs-dorzolamidetimolol-in-pati-a3725https://doaj.org/toc/1177-5467https://doaj.org/toc/1177-5483Miguel A Teus1, Stefano Miglior2, Guna Laganovska3, Lasma Volksone4, Bozena Romanowska-Dixon5, Roman Gos6, G&aacute;bor Holl&oacute;7, for the C-05-25 Study Group81Hospital Pr&iacute;ncipe de Ast&uacute;rias, Universidad de Alcal&aacute;, Madrid, Spain; 2Clinica Oculistica, Policlinico di Monza Universit&agrave; di Milano Bicocca, Monza (MI), Italy; 3Department of Ophthalmology, Stradina Clinical University Hospital, Riga, Latvia; 4Glaucoma Service, Clinical Hospital Gailezera, Riga, Latvia; 5Szpital Uniwersytecki w Krakowie, Krak&oacute;w, Poland; 6Contact-Med, Sp. z o.o., L&oacute;dz, Poland; 7Semmelweis University, Department of Ophthalmology, Budapest, Hungary; 8The C-05-25 Study Group: Members are listed under AcknowledgmentsPurpose: To compare the intraocular pressure- (IOP-) lowering efficacy of fixed combinations travoprost 0.004%/timolol 0.5% and dorzolamide 2%/timolol 0.5% in patients with ocular hypertension or open-angle glaucoma.Methods: In this prospective, multicenter, double-masked, randomized clinical trial, 319 qualifying patients received either travoprost/timolol once daily in the morning (n = 157) or dorzolamide/timolol twice daily (n = 162). IOP was assessed morning and evening at 2 and 6 weeks. The primary outcome measure was mean diurnal IOP. Results: Baseline mean IOP values were similar between groups. Mean pooled diurnal IOP was significantly lower in the travoprost/timolol group (16.5 mmHg &plusmn; 0.23) than in the dorzolamide/timolol group (17.3 mmHg &plusmn; 0.23; P = 0.011). Mean IOP was significantly lower in the travoprost/timolol group compared to the dorzolamide/timolol group at the 9 AM time point both at Week 2 (P = 0.006) and Week 6 (P = 0.002). The travoprost/timolol combination produced mean IOP reductions from baseline of 35.3% to 38.5%, while the dorzolamide/timolol combination produced mean IOP reductions from baseline of 32.5% to 34.5%. Conclusions: The fixed combination travoprost 0.004%/timolol 0.5% dosed once daily in the morning demonstrated superior mean diurnal IOP-lowering efficacy compared to dorzolamide 2%/timolol 0.5% dosed twice daily in patients with ocular hypertension or open-angle glaucoma.Keywords: dorzolamide, fixed combination, glaucoma, IOP-lowering therapy, timolol, travoprost Miguel A TeusStefano MigliorGuna Laganovskaet alDove Medical PressarticleOphthalmologyRE1-994ENClinical Ophthalmology, Vol 2009, Iss default, Pp 629-636 (2009)
institution	DOAJ
collection	DOAJ
language	EN
topic	Ophthalmology RE1-994
spellingShingle	Ophthalmology RE1-994 Miguel A Teus Stefano Miglior Guna Laganovska et al Efficacy and safety of travoprost/timolol vs dorzolamide/timolol in patients with open-angle glaucoma or ocular hypertension
description	Miguel A Teus1, Stefano Miglior2, Guna Laganovska3, Lasma Volksone4, Bozena Romanowska-Dixon5, Roman Gos6, G&aacute;bor Holl&oacute;7, for the C-05-25 Study Group81Hospital Pr&iacute;ncipe de Ast&uacute;rias, Universidad de Alcal&aacute;, Madrid, Spain; 2Clinica Oculistica, Policlinico di Monza Universit&agrave; di Milano Bicocca, Monza (MI), Italy; 3Department of Ophthalmology, Stradina Clinical University Hospital, Riga, Latvia; 4Glaucoma Service, Clinical Hospital Gailezera, Riga, Latvia; 5Szpital Uniwersytecki w Krakowie, Krak&oacute;w, Poland; 6Contact-Med, Sp. z o.o., L&oacute;dz, Poland; 7Semmelweis University, Department of Ophthalmology, Budapest, Hungary; 8The C-05-25 Study Group: Members are listed under AcknowledgmentsPurpose: To compare the intraocular pressure- (IOP-) lowering efficacy of fixed combinations travoprost 0.004%/timolol 0.5% and dorzolamide 2%/timolol 0.5% in patients with ocular hypertension or open-angle glaucoma.Methods: In this prospective, multicenter, double-masked, randomized clinical trial, 319 qualifying patients received either travoprost/timolol once daily in the morning (n = 157) or dorzolamide/timolol twice daily (n = 162). IOP was assessed morning and evening at 2 and 6 weeks. The primary outcome measure was mean diurnal IOP. Results: Baseline mean IOP values were similar between groups. Mean pooled diurnal IOP was significantly lower in the travoprost/timolol group (16.5 mmHg &plusmn; 0.23) than in the dorzolamide/timolol group (17.3 mmHg &plusmn; 0.23; P = 0.011). Mean IOP was significantly lower in the travoprost/timolol group compared to the dorzolamide/timolol group at the 9 AM time point both at Week 2 (P = 0.006) and Week 6 (P = 0.002). The travoprost/timolol combination produced mean IOP reductions from baseline of 35.3% to 38.5%, while the dorzolamide/timolol combination produced mean IOP reductions from baseline of 32.5% to 34.5%. Conclusions: The fixed combination travoprost 0.004%/timolol 0.5% dosed once daily in the morning demonstrated superior mean diurnal IOP-lowering efficacy compared to dorzolamide 2%/timolol 0.5% dosed twice daily in patients with ocular hypertension or open-angle glaucoma.Keywords: dorzolamide, fixed combination, glaucoma, IOP-lowering therapy, timolol, travoprost
format	article
author	Miguel A Teus Stefano Miglior Guna Laganovska et al
author_facet	Miguel A Teus Stefano Miglior Guna Laganovska et al
author_sort	Miguel A Teus
title	Efficacy and safety of travoprost/timolol vs dorzolamide/timolol in patients with open-angle glaucoma or ocular hypertension
title_short	Efficacy and safety of travoprost/timolol vs dorzolamide/timolol in patients with open-angle glaucoma or ocular hypertension
title_full	Efficacy and safety of travoprost/timolol vs dorzolamide/timolol in patients with open-angle glaucoma or ocular hypertension
title_fullStr	Efficacy and safety of travoprost/timolol vs dorzolamide/timolol in patients with open-angle glaucoma or ocular hypertension
title_full_unstemmed	Efficacy and safety of travoprost/timolol vs dorzolamide/timolol in patients with open-angle glaucoma or ocular hypertension
title_sort	efficacy and safety of travoprost/timolol vs dorzolamide/timolol in patients with open-angle glaucoma or ocular hypertension
publisher	Dove Medical Press
publishDate	2009
url	https://doaj.org/article/fe73aafe56dd429cb0d2fa9f00d86f07
work_keys_str_mv	AT miguelateus efficacyandsafetyoftravoprosttimololvsdorzolamidetimololinpatientswithopenangleglaucomaorocularhypertension AT stefanomiglior efficacyandsafetyoftravoprosttimololvsdorzolamidetimololinpatientswithopenangleglaucomaorocularhypertension AT gunalaganovska efficacyandsafetyoftravoprosttimololvsdorzolamidetimololinpatientswithopenangleglaucomaorocularhypertension AT etal efficacyandsafetyoftravoprosttimololvsdorzolamidetimololinpatientswithopenangleglaucomaorocularhypertension
_version_	1718398641496915968

Efficacy and safety of travoprost/timolol vs dorzolamide/timolol in patients with open-angle glaucoma or ocular hypertension

Ejemplares similares